Scientech Research LLC reduced its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 53.1% during the second quarter, Holdings Channel.com reports. The fund owned 1,182 shares of the company’s stock after selling 1,338 shares during the period. Scientech Research LLC’s holdings in Eli Lilly and Company were worth $1,070,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital Planning LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter worth $262,000. CHURCHILL MANAGEMENT Corp acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $6,916,000. M&G Plc bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at about $8,896,000. HighPoint Advisor Group LLC bought a new stake in Eli Lilly and Company in the fourth quarter worth approximately $9,878,000. Finally, Leo Wealth LLC bought a new stake in Eli Lilly and Company in the fourth quarter worth approximately $3,355,000. 82.53% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 8,848 shares of the company’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total value of $8,098,662.88. Following the completion of the transaction, the insider now owns 97,299,772 shares in the company, valued at approximately $89,059,454,309.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 423,559 shares of company stock worth $393,136,808. 0.13% of the stock is owned by company insiders.
Analyst Ratings Changes
Eli Lilly and Company Stock Performance
Shares of LLY stock opened at $877.50 on Friday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The firm has a 50-day moving average of $896.10 and a 200-day moving average of $842.91. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The company has a market cap of $833.98 billion, a P/E ratio of 129.23, a P/E/G ratio of 2.78 and a beta of 0.42.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Equities research analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.